Who are Reference0912's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tevimbra, Penpulimab kcqx, Loqtorzi, Unloxcyt, Jemperli, Libtayo.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/reference0912.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Reference0912 — Competitive Intelligence Brief

Reference0912 (Reference0912) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor. Area: Oncology.

phase 3 Immune checkpoint inhibitor PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Reference0912 (Reference0912) — Sun Pharma Advanced Research Company Limited. Reference0912 is a drug that targets the PD-1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reference0912 TARGET	Reference0912	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1
Tevimbra	TISLELIZUMAB	Beigene	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2025-01-01
Penpulimab kcqx	PENPULIMAB	Akeso Biopharma	marketed		Pd-1	2025-01-01
Loqtorzi	TORIPALIMAB	Coherus Biosciences Inc	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2024-01-01
Unloxcyt	COSIBELIMAB	Checkpoint Therapeutics Inc	marketed	Programmed Death Ligand-1 Blocker [EPC]	Pd-1	2024-01-01
Jemperli	DOSTARLIMAB	GSK	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	PD-1	2021-01-01
Libtayo	CEMIPLIMAB	Regeneron Pharmaceuticals	marketed		PD-1	2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor class)

Sun Pharma Advanced Research Company Limited · 2 drugs in this class
Brenda Cooper, MD · 1 drug in this class
Grace Therapeutics Inc. · 1 drug in this class
EMS · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Glycotope GmbH · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
HK inno.N Corporation · 1 drug in this class
Hanlim Pharm. Co., Ltd. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reference0912 — Competitive Intelligence Brief. https://druglandscape.com/ci/reference0912. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab